School of Medicine


Showing 1-4 of 4 Results

  • Katja Gabriele Weinacht, MD, PhD

    Katja Gabriele Weinacht, MD, PhD

    Assistant Professor of Pediatrics (Stem Cell Transplantation and Regenerative Medicine)

    Current Research and Scholarly Interests Pediatric Hematopoietic Stem Cell Transplantation
    DiGeorge Syndrome
    Genetic Immune Diseases
    Immune Dysregulation

  • John Fraser Wright

    John Fraser Wright

    Professor (Research) of Pediatrics (Stem Cell Transplantation)

    Bio J Fraser Wright, PhD
    Dr. Wright received his PhD in 1989 from the University of Toronto (Biochemistry) for studies
    characterizing the interaction of complement with IgM, and completed post-doctoral studies at INSERM
    / CENG Grenoble, France in molecular immunology focused on antigen processing and presentation. He
    was awarded a CRCS/ MRC Scholarship, gaining faculty appointment at the University of Toronto. In
    1996 he joined industry as a Scientist at Pasteur Sanofi, contributing there to the development of
    vaccines and cancer immunotherapies, and subsequently as Director of Development and Clinical
    Manufacturing at Avigen, a gene therapy company that pioneered AAV-based investigational gene
    therapies for hemophilia and Parkinson?s disease. In 2004 he returned to academia, establishing and
    directing the Clinical Vector Facility at the Center for Cellular and Molecular Therapeutics at Children?s
    Hospital of Philadelphia, and gaining faculty appointment at the University of Pennsylvania Perelman
    School of Medicine as professor of Pathology and Laboratory Medicine. Dr. Wright has contributed to
    several clinical development programs in gene therapy, including for Luxturna and Kymriah, the first
    gene therapies for a genetic (RPE65 deficiency) and non-genetic (CAR-T immunotherapy) disease,
    respectively, approved in the United States, and for the first gene therapy clinical trial that delivered an
    AAV-vectorized monoclonal antibody to human subjects for HIV passive immunity. He is a Co-founder of
    Spark Therapeutics, serving there and subsequently at Axovant as Chief Technology Officer. In 2019 Dr.
    Wright joined Stanford University as Professor of Pediatrics at The Center for Definitive and Curative
    Medicine (CDCM). His research program aims to address key immunological barriers to gene therapy
    through innovative approaches to viral vector design and generation, and to develop vectorized
    antibodies for serious human diseases.

Footer Links:

Stanford Medicine Resources: